Erratum: Crystal structures of novel non-peptidic, non-zinc chelating inhibitors bound to MMP-12 (Journal of Molecular Biology (2004) 341 (1063-1076) DOI: 10.1016/j.jmb.2004.06.039);Crystal structures of novel non-peptidic, non-zinc chelating inhibitors bound to MMP-12

Journal of Molecular Biology

Volumn 341, Issue 4, 2004, Pages 1063-1076

  Morales, Renaud ^a   Perrier, Sophie ^b   Florent, Jean Michel ^c   Beltra, Joel ^d   Dufour, Sylvie ^c   De Mendez, Isabelle ^e   Manceau, Peggy ^c   Tertre, Anita ^c   Moreau, François ^f   Compere, Delphine ^g   Dublanchet, Anne Claude ^h   O'Gara, Margaret ^c  

^a SANOFI   (France)

^b UNIV MONTPELLIER   (France)

^c PFIZER INC   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^e MEDIMMUNE LTD   (United Kingdom)

^f 156 Rue de Vaugirard   (France)

^g CEREP   (France)

^h L ORÉAL RECHERCHE   (France)

Author keywords

AH, acetohydroxamate; chronic obstructive pulmonary disease; COPD, chronic obstructive pulmonary disease; crystal structure; ECM, extracellular matrix; HTS, high throughput screening; macrophage metalloelastase; MMP 12; non zinc chelator

Indexed keywords

2 (1,3 DIOXO 1,3 DIHYDRO 2H ISOINDOL 2 YL)ETHYL 4 [4I ETHOXY (1,1I BIPHENYL) 4 YL]OXOBUTANOIC ACID; 3 [[4 [(PYRIDIN 4 YL)PHENYL]THIEN 2 YL]CARBOXAMIDO](PHENYL)PROPANOIC ACID; CHELATING AGENT; CP 271485; MACROPHAGE ELASTASE; PF 00356231; PF 0359601; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CATALYST; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG DESIGN; DRUG STRUCTURE; ENANTIOMER; HYDROPHOBICITY; PRIORITY JOURNAL; PROTEIN DOMAIN; RACEMIC MIXTURE;

EID: 3843152629     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2004.09.006     Document Type: Erratum

References (49)

1. Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell. 85:1996;299-302
2. Whittaker M., Floyd C.D., Brown P., Gearing A.J. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev. 99:1999;2735-2776
3. Borkakoti N. Structural studies of matrix metalloproteinases. J. Mol. Med. 78:2000;261-268
4. Bode W., Fernandez-Catalan C., Tschesche H., Grams F., Nagase H., Maskos K. Structural properties of matrix metalloproteinases. Cell. Mol. Life Sci. 55:1999;639-652
5. Murphy G., Hembry R.M., Hughes C.E., Fosang A.J., Hardingham T.E. Role and regulation of metalloproteinases in connective tissue turnover. Biochem. Soc. Trans. 18:1990;812-815
6. Nagase H., Fields G.B. Human matrix metalloproteinase specificity studies using collagen sequence-based synthetic peptides. Biopolymers. 40:1996;399-416
7. Pendas A.M., Knauper V., Puente X.S., Llano E., Mattei M.G., Apte S., et al. Identification and characterization of a novel human matrix metalloproteinase with unique structural characteristics, chromosomal location, and tissue distribution. J. Biol. Chem. 272:1997;4281-4286
8. Shapiro S.D., Griffin G.L., Gilbert D.J., Jenkins N.A., Copeland N.G., Welgus H.G., et al. Molecular cloning, chromosomal localization, and bacterial expression of a murine macrophage metalloelastase. J. Biol. Chem. 267:1992;4664-4671
9. Shapiro S.D., Kobayashi D.K., Ley T.J. Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages. J. Biol. Chem. 268:1993;23824-23829
10. Belaaouaj A., Shipley J.M., Kobayashi D.K., Zimonjic D.B., Popescu N., Silverman G.A., Shapiro S.D. Human macrophage metalloelastase. Genomic organization, chromosomal location, gene linkage, and tissue-specific expression. J. Biol. Chem. 270:1995;14568-14575
11. Wu L., Tanimoto A., Murata Y., Fan J., Sasaguri Y., Watanab T. Induction of human matrix metalloproteinase-12 gene transcriptional activity by GM-CSF requires the AP-1 binding site in human U937 monocytic cells. Biochem. Biophys. Res. Commun. 285:2001;300-307
12. Belvisi M.G., Bottomley K.M. The role of matrix metalloproteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD): a therapeutic role for inhibitors of MMPs. Inflamm. Res. 52:2003;95-100
13. Pouladi M.A., Robbins C.S., Swirski F.K., Cundall M., McKenzie A.N., Jordana M., Shapiro S.D., Staempfli M.R. Interleukin-13-dependent expression of matrix metalloproteinase-12 is required for the development of airway eosinophilia in mice. Am. J. Respir. Cell. Mol. Biol. 30:2004;84-90
14. Wu L., Tanimoto A., Murata Y., Sasaguri T., Fan J., Sasaguri Y., Watanabe T. Matrix metalloproteinase-12 gene expression in human vascular smooth muscle cells. Genes Cells. 8:2003;225-234
15. Woodside K.J., Hu M., Burke A., Murakami M., Pounds L.L., Killewich L.A., et al. Morphologic characteristics of varicose veins: possible role of metalloproteinases. J. Vasc. Surg. 38:2003;162-169
16. Becker J.W., Marcy A.I., Rokosz L.L., Axel M.G., Burbaum J.J., Fitzgerald P.M., et al. Stromelysin-1: three-dimensional structure of the inhibited catalytic domain and of the C-truncated proenzyme. Protein Sci. 4:1995;1966-1976
17. Betz M., Huxley P., Davies S.J., Mushtaq Y., Pieper M., Tschesche H., et al. 1.8-Å crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate primed-side inhibitor with a distinct selectivity profile. Eur. J. Biochem. 247:1997;356-363
18. Bode W., Reinemer P., Huber R., Kleine T., Schnierer S., Tschesche H. The X-ray crystal structure of the catalytic domain of human neutrophil collagenase inhibited by a substrate analogue reveals the essentials for catalysis and specificity. EMBO J. 13:1994;1263-1269
19. Botos I., Scapozza L., Zhang D., Liotta L.A., Meyer E.F. Batimastat, a potent matrix mealloproteinase inhibitor, exhibits an unexpected mode of binding. Proc. Natl Acad. Sci. USA. 93:1996;2749-2754
20. Spurlino J.C., Smallwood A.M., Carlton D.D., Banks T.M., Vavra K.J., Johnson J.S., et al. 1.56 Å structure of mature truncated human fibroblast collagenase. Proteins: Struct. Funct. Genet. 19:1994;98-109
21. Stams T., Spurlino J.C., Smith D.L., Wahl R.C., Ho T.F., Qoronfleh M.W., et al. Structure of human neutrophil collagenase reveals large S1′ specificity pocket. Nature Struct. Biol. 1:1994;119-123
22. Chen J.M., et al. Structure-based design of a novel, potent, and selective inhibitors for MMP-13 utilising NMR spectroscopy and computer aided molecular design. J. Am. Chem. Soc. 122:2000;9648-9654
23. Lang R., Kocourek A., Braun M., Tschesche H., Huber R., Bode W., Maskos K. Substrate specificity determinants of human macrophage elastase (MMP-12) based on the 1.1 Å crystal structure. J. Mol. Biol. 312:2001;731-742
24. Nar H., Werle K., Bauer M.M.T., Dollinger H., Jung B. Crystal structure of human macrophage elastase (MMP-12) in complex with a hydroxamic acid inhibitor. J. Mol. Biol. 312:2001;743-751
25. Terp G.E., Cruciani G., Christensen I.T., Jorgensen F.S. Structural differences of matrix metalloproteinases with potential implications for inhibitor selectivity examined by the GRID/CPCA approach. J. Med. Chem. 45:2002;2675-2684
26. Browner M.F., Smith W.W., Castelhano A.L. Matrilysin-inhibitor complexes: common themes among metalloproteases. Biochemistry. 34:1995;6602-6610
27. Akikazu M., et al. Crystal engineering for topochemical polymerisation of muconic esters using halogen-halogen and CH/pi interactions as weak intermolecular interactions. J. Am. Chem. Soc. 124:2002;8891-8902
28. Drummond A.H., Beckett P., Brown P.D., Bone E.A., Davidson A.H., Galloway W.A., et al. Preclinical and clinical studies of MMP inhibitors in cancer. Ann. NY Acad. Sci. 878:1999;228-235
29. Millar A.W., Brown P.D., Moore J., Galloway W.A., Cornish A.G., Lenehan T.J., Lynch K.P. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. Br. J. Clin. Pharmacol. 45:1998;21-26
30. Brandstetter H., Grams F., Glitz D., Lang A., Huber R., Bode W., et al. The 1.8-Å crystal structure of a matrix metalloproteinase 8-barbiturate inhibitor complex reveals a previously unobserved mechanism for collagenase substrate recognition. J. Biol. Chem. 276:2001;17405-17412
31. Lovejoy B., Welch A.R., Carr S., Luong C., Broka C., Hendricks R.T., et al. Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors. Nature Struct. Biol. 6:1999;217-221
32. Brandstetter H., Engh R.A., Von Roedern E.G., Moroder L., Huber R., Bode W., Grams F. Structure of malonic acid-based inhibitors bound to human neutrophil collagenase. A new binding mode explains apparently anomalous data. Protein Sci. 7:1998;1303-1309
33. Matter H., Schwab W., Barbier D., Billen G., Haase B., Neises B., et al. Quantitative structure-activity relationship of human neutrophil collagenase (MMP-8) inhibitors using comparative molecular field analysis and X-ray structure analysis. J. Med. Chem. 42:1999;1908-1920
34. Grams F., Crimmin M., Hinnes L., Huxley P., Pieper M., Tschesche H., Bode W. Structure determination and analysis of human neutrophil collagenase complexed with a hydroxamate inhibitor. Biochemistry. 34:1995;14012-14020
35. Pavlovsky A.G., Williams M.G., Ye Q.Z., Ortwine D.F., Purchase C.F. 2nd, White A.D., et al. X-ray structure of human stromelysin catalytic domain complexed with nonpeptide inhibitors: implications for inhibitor selectivity. Protein Sci. 8:1999;1455-1462
36. Chen L., Rydel T.J., Gu F., Dunaway C.M., Pikul S., Dunham K.M., Barnett B.L. Crystal structure of the stromelysin catalytic domain at 2.0 Å resolution: inhibitor-induced conformational changes. J. Mol. Biol. 293:1999;545-557
37. Natchus M.G., Cheng M., Wahl C.T., Pikul S., Almstead N.G., Bradley R.S., et al. Design and synthesis of conformationally-constrained MMP inhibitors. Bioorg. Med. Chem Lett. 8:1998;2077-2080
38. Dhanaraj V., Williams M.G., Ye Q.-Z., Molina F., Johnson L.L., Ortwine D.F., et al. X-ray structure of gelatinase a catalytic domain complexed with a hydroxamate inhibitor. Croat. Chem. Acta. 72:1999;575
39. Rowsell S., Hawtin P., Minshull C.A., Jepson H., Brockbank S.M., Barratt D.G., et al. Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor. J. Mol. Biol. 319:2002;173-181
40. Accelrys Inc. (2002). CNX Crystallography and NMR eXplorer 4.7, release 2002, San Diego, USA.
41. Knight C., Willenbrock F., Murphy G. A novel coumarin-labelled peptide for sensitive continuous assays of the matric metalloproteinases. FEBS Letters. 296:1992;263-266
42. Parkar A.A., Stow M.D., Smith K., Panicker A.K., Guilloteau J.P., Jupp R., Crowe S.J. Large-scale expression, refolding, and purification of the catalytic domain of human macrophage metalloelastase (MMP-12) in Escherichia coli. Protein Expt. Purif. 20:2000;152-161
43. Otwinowski, Z. & Minor, W. (1997). Processing of X-ray diffraction data collected in oscillation mode. In Methods in Enzymology Macromolecular Crystallography, part A (Carter, C. W. Jr & Sweet, R. M., eds), vol. 276, pp. 307-326.
44. Navaza. AmoRe: an automated package for molecular replacement. Acta Crystallog. sect. A. 50:1994;157-163
45. Engh R.A., Huber R. Accurate bond and angle parameters for X-ray protein structure refinement. Acta Crystallog. sect. A. 47:1991;392-400
46. Accelrys Inc. (2000). QUANTA release 2000, San Diego, USA.
47. Kleywegt G.J., Jones T.A. Model-building and refinement practice. Methods Enzymol. 277:1997;208-230
48. Laskowski R.A., MacArthur M.W., Moss D.S., Thornton J., M A program to check the stereochemical quality of protein structures. J. Appl. Crystallog. 26:1993;283-291
49. Sybyl® 6.92 Tripos Inc., 1699 South Hanley Rd., St. Louis, Missouri 63144, USA.